University thesis:
Dissertation, Georg-August-Universität Göttingen, 2021
Footnote:
Description:
Pancreatic cancer is a dismal malignancy with a 5-year survival rate of 7-9%, one of the worst among all cancer types. Patients with pancreatic ductal adenocarcinoma (PDAC) usually present an advanced stage of the disease upon diagnosis and often develop chemotherapy resistance. As the disease progresses, patients are commonly administered a gemcitabine-based therapy, which is known for its clinical benefits, but also low response and concomitant high resistance rates. For this reason, the mechanism driving gemcitabine resistance has been extensively studied in pancreatic cancer. In fact, s...